| Detected | Trial | Change |
|---|---|---|
| 2026-08-07 | NCT04386967 OH2 Injection in Solid Tumors |
Trial completed |
| 2026-08-07 | NCT04386967 OH2 Injection in Solid Tumors |
Enrollment increased: 30 -> 44 participants |
| 2026-08-07 | NCT04386967 OH2 Injection in Solid Tumors |
date change Primary completion pushed: 2026-03-13 -> 2026-06-02 |
| 2026-08-07 | NCT04386967 OH2 Injection in Solid Tumors |
date change Completion moved earlier: 2026-12-13 -> 2026-06-02 |
| 2026-08-06 | NCT05235074 OH2 Oncolytic Viral Therapy in Central Nervous System Tumors |
Trial completed |
| 2026-08-06 | NCT05235074 OH2 Oncolytic Viral Therapy in Central Nervous System Tumors |
Enrollment increased: 28 -> 40 participants |
| 2026-08-06 | NCT05235074 OH2 Oncolytic Viral Therapy in Central Nervous System Tumors |
date change Primary completion pushed: 2026-06-16 -> 2026-07-23 |
| 2026-08-06 | NCT05235074 OH2 Oncolytic Viral Therapy in Central Nervous System Tumors |
date change Completion pushed: 2026-06-16 -> 2026-07-23 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05868707 | OH2 Injection in Melanoma | Melanoma | Recruiting |
| Phase 1/2 | |||
| NCT05232136 | OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer | Non-muscle-invasive Bladder Cancer | Recruiting |
| NCT03866525 | OH2 Oncolytic Viral Therapy in Solid Tumors | Solid Tumor | Recruiting |
| NCT04616443 | OH2 Injection in Combination With HX008 for Melanoma. | Melanoma | Recruiting |
| NCT07382531 | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors | Solid Tumor | Recruiting |
| Phase 1 | |||
| NCT05698459 | OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with… | Advanced Liver Cancer | Recruiting |
| NCT05954091 | OH2 Administered by Intratumoral Injection | Solid Tumor | Not Yet Recruiting |